Boehringer Ingelheim diversifies sales with launches across multiple indications.
By Justin Burns, Analytics Analyst
30 June 2016
Boehringer Ingelheim will experience steady sales growth over the forecast period with blockbuster sales of key products across several therapy areas. Sales for Boehringer Ingelheim’s drugs will grow by $1.5bn at a compound annual growth rate of 1.1% out to 2025 due to key product sales in its respiratory, oncology, and endocrine portfolios.
Boehringer Ingelheim’s endocrine, metabolic, and genetic disorders portfolio will benefit greatly over the forecast period from the sales of diabetes drugs developed in partnership with Eli Lilly. Datamonitor Healthcare forecasts that the co-developed drugs – the Tradjenta/Ondero (linagliptin) franchise, the Jardiance (empagliflozin) franchise, Basaglar/Abasria (insulin glargine), and Glyxambi (empagliflozin/linagliptin) – will provide Boehringer Ingelheim with combined returns of $3.4bn by 2025.
Boehringer Ingelheim successfully entered the lucrative oncology market in 2013 when the U.S. Food and Drug Administration approved Gilotrif (afatinib) for the treatment of non-small cell lung cancer (NSCLC). Datamonitor Healthcare expects the product to carve out a moderate share of the NSCLC market and forecasts Gilotrif to reach peak revenues of over $1bn in 2025 when including sales for head and neck cancer. Boehringer Ingelheim is furthering its presence in oncology with Vargatef (nintedanib), a triple angiokinase inhibitor that is under development in multiple tumor types. Pivotal studies for Vargatef are being conducted in metastatic colorectal cancer and NSCLC.
Boehringer Ingelheim’s therapy area dynamics, 2015–25Datamonitor Healthcare’s company analysis on Boehringer Ingelheim explores global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>